Spectrum Pharmaceuticals, Inc. ("Spectrum") is an American biopharmaceutical company focused on developing oncology therapies.

According to a law firm press release, the Complaint alleges on October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. When the truth was revealed, shares dropped causing investors harm.

This case was voluntarily dismissed on December 11, 2015.